Maat Pharma (XPAR:MAAT) Operating Margin %: -714.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MAAT Maat Pharma SA XPAR:MAAT
27 GF Score
Price €2.73
GF Value €10.63
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Maat Pharma Operating Margin %?

Maat Pharma XPAR:MAAT +1.30% 27 Operating Margin % is -714.40% as of Dec. 2025. GuruFocus rates XPAR:MAAT with a GF Score™ of 27/100 and a GF Value™ of €10.63 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 940 Biotechnology companies, Maat Pharma ranks worse than 73.3% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Maat Pharma's Operating Income for the six months ended in Dec. 2025 was €-14.98 Mil. Maat Pharma's Revenue for the six months ended in Dec. 2025 was €2.10 Mil. Therefore, Maat Pharma's Operating Margin % for the quarter that ended in Dec. 2025 was -714.40%.

The historical rank and industry rank for Maat Pharma's Operating Margin % or its related term are showing as below:

XPAR:MAAT' s Operating Margin % Range Over the Past 10 Years
Min: -947.97   Med: -895.15   Max: -657.16
Current: -657.16


XPAR:MAAT's Operating Margin % is ranked worse than
73.3% of 940 companies
in the Biotechnology industry
Industry Median: -86.55 vs XPAR:MAAT: -657.16

Maat Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Maat Pharma's Operating Income for the six months ended in Dec. 2025 was €-14.98 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €-29.73 Mil.


Maat Pharma  (XPAR:MAAT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Maat Pharma Operating Margin % Related Terms


Maat Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Maat Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maat Pharma Operating Margin % Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -914.81 -947.97 -895.15 -883.99 -657.16

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,342.35 -741.20 -1,048.36 -607.70 -714.40

XPAR:MAAT vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Maat Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Maat Pharma's Operating Margin % falls into.


XPAR:MAAT
27GF Score
Maat Pharma SA XPAR:MAAT
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maat Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Maat Pharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-29.73 / 4.524
=-657.16 %

Maat Pharma's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-14.981 / 2.097
=-714.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -714.40% mean?
Maat Pharma (XPAR:MAAT) has a Operating Margin % of -714.40% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Maat Pharma and its competitors. According to the industry distribution chart, Maat Pharma ranks #689 out of 940 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Maat Pharma's Operating Margin % too high?
Maat Pharma's current Operating Margin % is -714.40%. Based on the distribution chart, Maat Pharma ranks #689 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #689 out of 940 companies for Operating Margin %. This places Maat Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Maat Pharma and its competitors. Maat Pharma's current Operating Margin % is -714.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.63, compared to a current price of €2.73 — trading 74.4% below its estimated fair value. The current Operating Margin % is -714.40%. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current Operating Margin % is -714.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?

Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued. The current stock price of €2.73 is trading 74.4% below its estimated GF Value™ of €10.63. GuruFocus considers Maat Pharma to be Possible Value Trap.

Key valuation signals for XPAR:MAAT:

  • Operating Margin %: -714.40%
  • GF Value™: €10.63 vs. price of €2.73 (74.4% below fair value)
  • GF Score™: 27/100 with 3 warning signs

No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maat Pharma Business Description

Other Exchanges 4RD:Germany
Address 70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score

Get the complete analysis for XPAR:MAAT

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.73
Price
€10.63
GF Value